GVS advice avatrombopag (Doptelet®) for the treatment of thrombocytopenia
The National Health Care Institute has completed its assessment whether avatrombopag (Doptelet®) is interchangeable with a product that is included in the Medicine Reimbursement System (GVS). Avatrombopag (Doptelet®) is indicated for the treatment of thrombocytopenia. The National Health Care Institute recommends to include avatrombopag (Doptelet®) with eltrombopag (Revolade®) in the newly formed cluster on List 1A of the GVS.
Registered indication
Avatrombopag (Doptelet®) is indicated for the treatment of:
- primary chronic immune thrombocytopenia (ITP) in adult patients resistant to other treatments (e.g. corticosteroids, immunoglobulins);
- severe thrombocytopenia in adult patients with chronic liver disease scheduled for an invasive procedure.
Avatrombopag is available as a film-coated tablet.
Review of interchangeability
On the basis of the criteria for interchangeability, it can be concluded that avatrombopag is interchangeable with eltrombopag (Revolade®).
The National Health Care Institute's advice
The National Health Care Institute advises the Minister to include avatrombopag (Doptelet®) with eltrombopag (Revolade®) in the newly formed cluster on List 1A of the GVS. 20 mg/day can be applied as the standard dose for avatrombopag. The standard dose for eltrombopag can be set at 50 mg per day.